Regen BioPharma, Inc.
RGBP
$0.0548
$0.00479.38%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 96.24% | -94.56% | -103.61% | -6.20% | 15.46% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | 0.00% | -21.25% | 272.09% | 0.00% | -2.27% |
| Total Other Non-Cash Items | -100.00% | -96.58% | 6,513.04% | -- | -- |
| Change in Net Operating Assets | -121.92% | 929.23% | -5.91% | 46.16% | -318.35% |
| Cash from Operations | -52.41% | 55.41% | 13.73% | 17.53% | -28.96% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | 56.38% | 244.50% | -- | -- | -- |
| Total Debt Repaid | -- | -- | 92.86% | 184.00% | 46.24% |
| Issuance of Common Stock | -- | -- | -79.23% | -27.99% | -11.49% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 56.38% | -25.06% | -43.83% | -4.05% | -1.75% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 366.67% | 99.02% | -274.85% | 64.87% | -1,425.71% |